In a trial of the anti-PD-1 antibody pembrolizumab [3], subgroup analysis indicated that PD-L1 expression on tumor cells is a potential predictive factor of the response to anti-PD-1 antibodies [4]. This evidence concerns the gene PDCD1 and neoplasm.